TMCnet News
Immunomic Therapeutics, Inc. Scientist Presenting at International Society for Vaccines Annual CongressOn Sunday, Oct. 2, Immunomic Therapeutics Inc.'s scientist, Dr. Franco Pissani, will offer an oral presentation during the International Society for Vaccines' Annual Congress. The presentation will examine how the LAMP-Vax™ platform technology was applied in the formulation and testing of a peanut allergy mouse model and DNA vaccine coding for sequences of peanut allergens and LAMP-Vax. Who: Dr. Franco Pissani, Immunomic Therapeutics, Inc. Scientist
When: Oct. 2, 3 pm EST Where: Mechanisms of Immune Efficacy Session at The Boston Marriot Long Wharf at 296 State St, Boston, MA 02109 About ITI Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing a new generation of nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive technology works with the body's natural biochemistry system and has the potential to improve a broad range of vaccines. Immunomic Therapeutics successfully licensed their allergy platform to Astellas Pharma in 2015 and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005896/en/ |
